Literature DB >> 25653863

Efficacy of reduced-dose regimen of a capsule containing bismuth subcitrate, metronidazole, and tetracycline given with amoxicillin and esomeprazole in the treatment of Helicobacter Pylori infection.

Ali H Harb1, Zeinab D El Reda1, Fayez S Sarkis1, Hani F Chaar1, Ala I Sharara1.   

Abstract

It is well known that triple therapy for Helicobacter pylori is losing efficacy worldwide. A regimen containing proton pump inhibitor and multiple-dose capsules of bismuth, metronidazole, and tetracycline has proven efficacy. In addition, a literature review on dosage of previous regimens shows that half-dose clarithromycin-based regimens are equally effective to full-dose regimens. However, the applicability of dose reduction to bismuth-based therapy is unknown. This communication shows that a reduced-dose bismuth-based regimen fails to achieve acceptable eradication rates.

Entities:  

Keywords:  Helicobacter pylori; adverse events; eradication

Year:  2015        PMID: 25653863      PMCID: PMC4315687          DOI: 10.1177/2050640614560787

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  4 in total

1.  Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: a 10-year follow-up study.

Authors:  A Tursi; W Elisei; G Giorgetti; M Picchio; G Brandimarte
Journal:  Panminerva Med       Date:  2014-03       Impact factor: 5.197

2.  Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.

Authors:  Peter Malfertheiner; Franco Bazzoli; Jean-Charles Delchier; Krysztof Celiñski; Monique Giguère; Marc Rivière; Francis Mégraud
Journal:  Lancet       Date:  2011-02-21       Impact factor: 79.321

Review 3.  Epidemiology and diagnosis of Helicobacter pylori infection.

Authors:  Ante Tonkic; Marija Tonkic; Philippe Lehours; Francis Mégraud
Journal:  Helicobacter       Date:  2012-09       Impact factor: 5.753

4.  American College of Gastroenterology guideline on the management of Helicobacter pylori infection.

Authors:  William D Chey; Benjamin C Y Wong
Journal:  Am J Gastroenterol       Date:  2007-06-29       Impact factor: 10.864

  4 in total
  3 in total

1.  Chitosan Inhibits Helicobacter pylori Growth and Urease Production and Prevents Its Infection of Human Gastric Carcinoma Cells.

Authors:  Shun-Hsien Chang; Pei-Ling Hsieh; Guo-Jane Tsai
Journal:  Mar Drugs       Date:  2020-10-29       Impact factor: 5.118

Review 2.  The Challenges of Eradicating Pediatric Helicobacter pylori Infection in the Era of Probiotics.

Authors:  Lorena Elena Meliț; Cristina Oana Mărginean; Maria Oana Săsăran
Journal:  Children (Basel)       Date:  2022-05-28

Review 3.  Helicobacter pylori treatment: antibiotics or probiotics.

Authors:  Kamila Goderska; Sonia Agudo Pena; Teresa Alarcon
Journal:  Appl Microbiol Biotechnol       Date:  2017-10-26       Impact factor: 4.813

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.